Latest Biotech News

Page 31 of 35
Nyrada Inc. has cleared the Safety Review Committee’s scrutiny for its Phase I clinical trial, progressing to the third dosing cohort of its promising neuroprotective and cardioprotective drug candidate NYR-BI03.
Ada Torres
Ada Torres
2 May 2025
Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.
Ada Torres
Ada Torres
1 May 2025
BluGlass Limited has achieved a world-record 1250mW single-mode GaN laser chip and strengthened its commercial pipeline with a $120,000 repeat order, positioning itself for rapid growth in photonics markets.
Sophie Babbage
Sophie Babbage
30 Apr 2025
Hexima Limited reported a stable cash position of $1.55 million at quarter-end, with a modest $87,000 net cash outflow from operations. The biotech company continues to explore strategic opportunities while maintaining a strong funding runway.
Ada Torres
Ada Torres
30 Apr 2025
EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.
Ada Torres
Ada Torres
30 Apr 2025
Imagion Biosystems has progressed its MagSense HER2 breast cancer imaging agent towards a pivotal Investigational New Drug application with the FDA, backed by a solid funding runway exceeding 13 quarters.
Ada Torres
Ada Torres
30 Apr 2025
Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.
Ada Torres
Ada Torres
30 Apr 2025
Starpharma reports steady progress in its DEP® drug development programs, launches new marketing campaigns in key regions, and maintains a strong cash position of $17.2 million as it refines clinical strategies and partnerships.
Ada Torres
Ada Torres
30 Apr 2025
Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.
Ada Torres
Ada Torres
30 Apr 2025
INOVIQ Limited reports significant progress in its exosome-based cancer diagnostics and therapeutics, including expanded customer adoption, advanced AI screening tests, and strategic partnerships with leading research centres.
Ada Torres
Ada Torres
30 Apr 2025
Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.
Ada Torres
Ada Torres
30 Apr 2025
Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.
Ada Torres
Ada Torres
30 Apr 2025